Imunon 대차 대조표 상태

재무 상태 기준 확인 6/6

Imunon has a total shareholder equity of $3.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $9.7M and $6.0M respectively.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$5.31m
주식	US$3.74m
총 부채	US$5.95m
총 자산	US$9.69m

최근 재무 상태 업데이트

Recent updates

재무 상태 분석

단기부채: CBO's short term assets ($7.6M) exceed its short term liabilities ($5.1M).

장기 부채: CBO's short term assets ($7.6M) exceed its long term liabilities ($872.9K).

부채 대 자본 내역 및 분석

부채 수준: CBO is debt free.

부채 감소: CBO has no debt compared to 5 years ago when its debt to equity ratio was 51%.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: CBO has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.

예측 현금 활주로: CBO is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.

Imunon 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Imunon Receives Non-Compliance Notice From Nasdaq

Recent updates

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

New major risk - Financial position

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New major risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

New major risk - Share price stability

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Full year 2022 earnings released: US$5.03 loss per share (vs US$3.83 loss in FY 2021)

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Third quarter 2022 earnings released: US$0.87 loss per share (vs US$0.94 loss in 3Q 2021)

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

First half 2022 earnings released: US$2.86 loss per share (vs US$4.26 loss in 1H 2021)

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings released: US$1.82 loss per share (vs US$1.29 loss in 1Q 2021)

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Full year 2021 earnings released: US$3.83 loss per share (vs US$10.08 loss in FY 2020)

Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Celsion Corporation announced that it expects to receive $28.5 million in funding

Third quarter 2021 earnings released: US$0.063 loss per share (vs US$0.24 loss in 3Q 2020)

Celsion Corporation Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform

First half 2021 earnings released: US$0.15 loss per share (vs US$0.37 loss in 1H 2020)

Celsion Corporation Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer

Celsion Corporation(NasdaqCM:CLSN) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: US$0.086 loss per share (vs US$0.20 loss in 1Q 2020)

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.77 loss in FY 2019)

Celsion Corporation Announces Update on Phase I/II Ovation 2 Study

Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores

Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (Nol) Program

Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Announces Formation of Vaccine Advisory Board

New 90-day high: €1.82

Celsion Corporation Files Provisional U.S. Patent Application for A Broad Range of Next Generation DNA Vaccines

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $34.999999 million.

New 90-day high: €0.78

Celsion Corporation Announces the Retirement of Dr. Alberto Martinez from the Board of Directors